Translate
Myriad Genetics Inc
About
Myriad Genetics Inc (NASDAQ:MYGN) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 16 2026
Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026
Apr 14 2026
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan
Apr 9 2026
Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting
Mar 17 2026
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
Mar 17 2026
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
Financials
Revenue
$557 M
Market Cap
$444.16 M
EPS
-3.95